Active Peptic Ulcer Disease disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: ACT058 MIFTS: 54	Active Peptic Ulcer Disease Categories: Gastrointestinal diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Active Peptic Ulcer Disease

MalaCards integrated aliases for Active Peptic Ulcer Disease:

Name: Active Peptic Ulcer Disease ¹¹ ¹⁴

Gi Bleeding ¹¹ ¹⁴

Gastrointestinal Hemorrhage ⁷¹

Active Peptic Ulcer ⁷¹

Classifications:

MalaCards categories:
Anatomical: Gastrointestinal diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:749

UMLS ⁷¹ C0017181 C1706705

Sources

Summaries for Active Peptic Ulcer Disease

MalaCards based summary: Active Peptic Ulcer Disease, also known as gi bleeding, is related to dieulafoy lesion and gastrointestinal stromal tumor, and has symptoms including nausea and vomiting, constipation and vomiting. An important gene associated with Active Peptic Ulcer Disease is ATP12A (ATPase H+/K+ Transporting Non-Gastric Alpha2 Subunit), and among its related pathways/superpathways are Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) and Angiogenesis (CST). The drugs Levofloxacin and Ofloxacin have been mentioned in the context of this disorder. Affiliated tissues include liver, colon and kidney, and related phenotypes are homeostasis/metabolism and normal

Sources

Related Diseases for Active Peptic Ulcer Disease

Diseases related to Active Peptic Ulcer Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 621)

#	Related Disease	Score	Top Affiliating Genes
1	dieulafoy lesion	30.9	F2 ATP4A ATP12A
2	gastrointestinal stromal tumor	30.4	SST KIT ANO1 ALB
3	arteriovenous malformation	30.4	VWF F3 F2 ALB ACVRL1
4	intestinal tuberculosis	30.3	CRP ALB
5	klippel-trenaunay-weber syndrome	30.2	SST F2 ACVRL1
6	esophagitis	30.2	PTGS2 HRH2 CYP2C19
7	endocarditis	30.1	F2 CRP ALB
8	leech infestation	30.1	F3 F2 CYGB
9	thrombophilia due to thrombin defect	30.1	VWF F3 F2
10	iron deficiency anemia	30.1	CYGB CRP ATP4A
11	splenic artery aneurysm	30.1	F2 ATP4A ATP12A ACVRL1
12	aortic aneurysm	30.1	F3 F2 CRP ALB
13	atrophic gastritis	30.1	SST PTGS2 ATP4A ATP12A
14	duodenal ulcer	30.1	SST HRH2 CYP2C19
15	angiodysplasia	30.1	VWF SST F3 F2 ATP4A ATP12A
16	hypersensitivity vasculitis	30.1	F2 CRP ALB
17	vascular cancer	30.0	VWF KIT ANO1
18	meckel diverticulum	30.0	SST KIT CRP ATP4A ATP12A ALB
19	cavernous hemangioma	30.0	VWF F3 F2 ALB
20	chronic intestinal vascular insufficiency	30.0	CRP ATP4A ATP12A ALB
21	anus disease	30.0	CRP ATP4A ATP12A ALB
22	uremia	30.0	VWF CRP ALB
23	vitamin k deficiency bleeding	29.9	F7 F3 F2
24	factor vii deficiency	29.9	F7 F3 F2
25	purpura	29.9	VWF F3 F2 CRP
26	ischemic colitis	29.9	F3 F2 CRP ATP4A ATP12A ALB
27	intussusception	29.8	KIT CRP ANO1 ALB
28	acquired von willebrand syndrome	29.8	VWF F7 F3 F2
29	aortic aneurysm, familial thoracic 1	29.8	VWF CRP ALB ACVRL1
30	alcohol use disorder	29.8	GPT F2 CRP ATP12A ALB
31	vascular disease	29.8	VWF PTGS2 F3 F2 CRP ALB
32	zollinger-ellison syndrome	29.8	SST HRH2 ATP4A ATP12A
33	cholecystitis	29.7	GPT F2 CRP ALB
34	behcet syndrome	29.7	VWF F3 F2 CRP ALB
35	liver cirrhosis	29.7	SST GPT F3 F2 ALB
36	neurofibromatosis, type i	29.7	SST KIT ANO1
37	diarrhea	29.6	VWF SST HRH2 GPT ALB
38	factor viii deficiency	29.6	VWF F7 F3 F2 ALB
39	hernia, hiatus	29.5	HRH2 CYP2C19 CRP ATP4A ATP12A ALB
40	obstructive jaundice	29.4	SST GPT F2 CRP ALB
41	acute myocardial infarction	29.4	VWF F7 F3 F2 CRP ALB
42	esophageal varix	29.4	SST GPT F3 F2 CRP ATP4A
43	inguinal hernia	29.3	KIT GPT F3 F2 CRP ALB
44	portal hypertension	29.3	SST PTGS1 GPT F2 ALB
45	hemorrhoid	29.3	GPT F3 F2 CRP ATP4A ATP12A
46	aspiration pneumonia	29.2	GPT F3 F2 CRP ATP4A ATP12A
47	intestinal obstruction	29.2	KIT GPT F2 CRP ATP4A ATP12A
48	gastroesophageal reflux	29.2	PTGS2 PTGS1 HRH2 CYP2C19 ATP4A ATP12A
49	gastritis	29.1	SST PTGS2 PTGS1 HRH2 CYP2C19 ATP4A
50	gastric ulcer	29.1	SST PTGS2 PTGS1 HRH2 CYP2C19 ATP12A

Comorbidity relations with Active Peptic Ulcer Disease via Phenotypic Disease Network (PDN): (show top 50) (show all 144)

Acquired Thrombocytopenia	Acute Cystitis
Acute Kidney Failure	Acute Myocardial Infarction
Acute Pancreatitis	Acute Vascular Insufficiency of Intestine
Alcohol Use Disorder	Alcoholic Gastritis
Alcoholic Hepatitis	Alcoholic Liver Cirrhosis
Alzheimer Disease, Familial, 1	Anus Disease
Aortic Valve Disease 1	Ascending Colon Cancer
Atrophic Gastritis	Bacteremia 2
Benign Essential Hypertension	Bleeding Disorder, Platelet-Type, 11
Bronchitis	Bronchopneumonia
Candidiasis	Cardiac Arrest
Cardiogenic Shock	Cecal Benign Neoplasm
Cerebral Atherosclerosis	Cerebrovascular Disease
Cholestasis	Chronic Intestinal Vascular Insufficiency
Chronic Kidney Disease	Chronic Pulmonary Heart Disease
Chronic Ulcer of Skin	Chylomicron Retention Disease
Colon Carcinoma in Situ	Colorectal Cancer
Conjunctivitis	Crohn's Disease
Cystitis	Decubitus Ulcer
Deficiency Anemia	Dermatomycosis
Descending Colon Cancer	Disseminated Intravascular Coagulation
Duodenitis	Duodenum Cancer
Dysthymic Disorder	Encephalopathy
Epilepsy, Focal, with Speech Disorder and with or Without Impaired Intellectual Development	Esophageal Cancer
Esophageal Candidiasis	Esophageal Disease

Graphical network of the top 20 diseases related to Active Peptic Ulcer Disease:

Sources

Symptoms & Phenotypes for Active Peptic Ulcer Disease

UMLS symptoms related to Active Peptic Ulcer Disease:

nausea and vomiting; constipation; vomiting; fatigue; fever; hemoptysis; abdominal pain; chest pain; headache; pruritus; syncope; diarrhea; edema; pain; nausea; chronic pain; sciatica; halitosis; dyspepsia; icterus; coughing; vertigo/dizziness; heartburn; gastrointestinal gas; symptoms; digestive system symptom; pelvic pain; blood in stool

GenomeRNAi Phenotypes related to Active Peptic Ulcer Disease according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	no effect	GR00402-S-1	10.18	ACVRL1 ALB ANO1 ATP12A ATP4A CRP
2	no effect	GR00402-S-2	10.18	ACVRL1 ALB ANO1 ATP12A ATP4A CRP

MGI Mouse Phenotypes related to Active Peptic Ulcer Disease:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.09	ACVRL1 ALB ANO1 ATP12A ATP4A CRP
2	normal	MP:0002873	10.02	ACVRL1 ALB F2 F3 F7 KIT
3	neoplasm	MP:0002006	9.95	ALB ATP4A CYGB F3 KIT PTGS1
4	renal/urinary system	MP:0005367	9.92	ACVRL1 ALB ANO1 ATP12A CYGB KIT
5	muscle	MP:0005369	9.91	ACVRL1 ALB ANO1 CYGB F2 F3
6	digestive/alimentary	MP:0005381	9.73	ACVRL1 ALB ANO1 ATP12A ATP4A F2
7	cardiovascular system	MP:0005385	9.4	ACVRL1 ALB ANO1 CRP CYGB F2

Sources

Drugs & Therapeutics for Active Peptic Ulcer Disease

Drugs for Active Peptic Ulcer Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 181)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Levofloxacin

Approved, Investigational

Phase 4

100986-85-4

149096

Ofloxacin

Approved

Phase 4

82419-36-1

4583

Metronidazole

Approved

Phase 4

443-48-1, 69198-10-3

4173

Prucalopride

Approved

Phase 4

179474-81-8

3052762

Famotidine

Approved

Phase 4

76824-35-6

3325 5702160

Histamine

Approved, Investigational

Phase 4

51-45-6

774

Clopidogrel

Approved

Phase 4

120202-66-6, 113665-84-2

60606

Somatostatin

Approved, Investigational

Phase 4

38916-34-6, 51110-01-1

53481605 16129706

Terlipressin

Approved, Investigational

Phase 4

14636-12-5

72081

Nadolol

Approved

Phase 4

42200-33-9

39147

Propranolol

Approved, Investigational

Phase 4

318-98-9, 525-66-6

62882 4946

Ceftriaxone

Approved

Phase 4

73384-59-5

5479530

Isosorbide dinitrate

Approved, Investigational

Phase 4

87-33-2

3780 6883

Isosorbide

Approved, Investigational

Phase 4

652-67-5

99937 12597

Nitric Oxide

Approved

Phase 4

10102-43-9

145068

Prazosin

Approved

Phase 4

19216-56-9

4893

Warfarin

Approved

Phase 4

81-81-2, 129-06-6

54678486

Heparin, bovine

Approved, Investigational, Withdrawn

Phase 4

9005-49-6

22833565 9812414 772

Reviparin

Approved, Investigational

Phase 4

9041-08-1

Midodrine

Approved

Phase 4

133163-28-7, 42794-76-3

4195

Rabeprazole

Approved, Investigational

Phase 4

117976-89-3, 117976-90-6

5029

Linaclotide

Approved

Phase 4

851199-59-2

16158208

Bemiparin

Approved, Investigational

Phase 4

91449-79-5

Acenocoumarol

Approved, Investigational

Phase 4

152-72-7

54676537 9052

Phylloquinone

Approved, Investigational

Phase 4

84-80-0

5284607

Thrombin

Approved, Investigational

Phase 4

Misoprostol

Approved

Phase 4

59122-46-2

5282381

Octreotide

Approved, Investigational

Phase 4

83150-76-9

383414 6400441

Dopamine

Approved

Phase 4

62-31-7, 51-61-6

681

Ondansetron

Approved, Withdrawn

Phase 4

99614-02-5

4595

Bisacodyl

Approved

Phase 4

603-50-9

2391

Iron

Approved

Phase 4

7439-89-6

29936

Amoxicillin

Approved, Vet_approved

Phase 4

26787-78-0

33613

Menadione

Approved, Nutraceutical

Phase 4

58-27-5

4055

Menaquinone

Investigational

Phase 4

1182-68-9

Antiprotozoal Agents

Phase 4

Antiparasitic Agents

Phase 4

Cathartics

Phase 4

Laxatives

Phase 4

Serotonin Receptor Agonists

Phase 4

Histamine phosphate

Phase 4

51-74-1

134614

Histamine H2 Antagonists

Phase 4

Histamine Antagonists

Phase 4

Platelet Aggregation Inhibitors

Phase 4

Anticoagulants

Phase 4

Hormones

Phase 4

Antihypertensive Agents

Phase 4

Hormone Antagonists

Phase 4

Adrenergic beta-Antagonists

Phase 4

Adrenergic Antagonists

Phase 4

Interventional clinical trials:

(show top 50) (show all 252)

#	Name	Status	NCT ID	Phase	Drugs
1	Intravenous Administration of Metronidazole, Levofloxacin and Esomeprazole Triple Therapy in the Treatment of Helicobacter Pylori Infection and Related Complications Caused by Active Peptic Ulcer Disease	Unknown status	NCT04432233	Phase 4	Esomeprazole;Metronidazole;Levofloxacin
2	The Effect of Prucalopride on Small Bowel Transit Time in Patients Undergoing Capsule Endoscopy: A Randomized Controlled Trial	Unknown status	NCT02806206	Phase 4	Prucalopride;Placebo
3	The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Continuing or Discontinuing on Aspirin: a Multicenter, Double-blind, Placebo-controlled, Randomized Clinical Trial	Unknown status	NCT01549418	Phase 4	Aspirin (ASA);Placebo
4	The Comparison of Oral Rabeprazole vs. Intravenous Omeprazole in the Treatment of Patients With Mild to Moderate Nonvariceal Upper Gastrointestinal Bleeding	Unknown status	NCT00861640	Phase 4	Intravenous Omeprazole;Oral Rabeprazole
5	Efficacy and Safety of Early Administration of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding: a Multicenter, Randomized, Double Blind, Placebo-controlled Trial (Modified by amendment1)	Unknown status	NCT03023189	Phase 4	Tranexamic acid;Placebo
6	Randomized and Controlled Clinical Trial of Transfusional Requirements in Patients With Acute Gastrointestinal Bleeding.	Unknown status	NCT00414713	Phase 4
7	Prospective, Randomized Trial of Hemospray Plus Epinephrine Injection Versus Endoscopic Hemoclip Plus Epinephrine Injection in Nonvariceal Upper Gastrointestinal Bleeding	Unknown status	NCT02537353	Phase 4	Hemospray;Adrenaline
8	A Double Blind Study Comparing Low Dose and High Dose IV Esomeprazole After Successful Endoscopic Therapy in Patients With Peptic Ulcer Bleeding	Unknown status	NCT01275937	Phase 4	Esomeprazole;esomeprazole
9	Platelet Inhibitory Effect of Clopidogrel in Patients Treated With Omeprazole, Pantoprazole, or Famotidine	Completed	NCT00950339	Phase 4	omeprazole, 20mg twice daily;famotidine 40mg twice daily;pantoprazole 40mg once daily
10	Sup-Icu RENal (SIREN) - a Sub-analysis of the Prospective SUP (Stress Ulcer Prophylaxis)-ICU Trial on the Risk of GI- Bleeding in ICU Patients Receiving Renal Replacement Therapy	Completed	NCT02718261	Phase 4	Pantoprazole;Saline 0.9% (matching placebo)
11	Local Administration of Tranexamic Acid in Upper Gastrointestinal Hemorrhage: A Double-Blind, Randomized, Placebo-Controlled Trial	Completed	NCT02903017	Phase 4	Tranexamic acid 5%;Placebo
12	Comparison of 3 Days and 7 Days Intravenous Ceftriaxone Prophylaxis in Patients With Acute Variceal Bleeding	Completed	NCT00838864	Phase 4	ceftrioxone
13	Secondary Prophylaxis After Variceal Bleeding: Combined Treatment With Endoscopic Ligation and Nadolol Against Nadolol Associated With Mononitrate of Isosorbide or Prazosin According to Hemodynamic Response.	Completed	NCT00450164	Phase 4	Nadolol;Isosorbide mononitrate;Prazosin
14	A Multi-centre Proof of Concept Study to Assess Efficacy and Safety of a New Liquid Endoscopic Hemostatic Agent (Seraseal / Fastact ®) in Patients With Active Gastrointestinal Bleeding	Completed	NCT02349490	Phase 4
15	A Randomized, Controlled, Multicentric Trial Comparing Endoscopic Band Ligation Versus Ransjugular Intrahepatic Portosystemic Stent Shunt in Cirrhotic Patients With Recurrent Variceal Bleeding Non Responding to Medical Therapy	Completed	NCT00570973	Phase 4
16	Comparison of the Efficacy of Compliant Oral Iron Treatment (FerroDuretter ®) for 3 Months After Discharge Versus Single-dose of Intravenous Iron (Ferinject ®) Before Discharge in Patients With Acute Bleeding From Upper Gastrointestinal Tract. A Double Blinded Randomized Trial	Completed	NCT00978575	Phase 4	ferricarboxymaltose;Ferrosulfate;Placebo
17	Single Blind, Randomized, Controlled Trial of Conventional Versus Split-Dose Bowel Preparation for Inpatient Colonoscopy	Completed	NCT01169220	Phase 4	Go-Lytely;Go Lytely
18	Midodrine and Albumin for Cirrhotic Patients in the Waiting List for Liver Transplantation	Completed	NCT00839358	Phase 4	albumin;Midodrine;Placebo
19	The Dissemination of Consensus Recommendations on the Management of Canadian Patients With Non Variceal Upper Gastrointestinal Bleeding: A National Cluster Randomized Trial of a Multifaceted Tailored Implementation Strategy	Completed	NCT00840008	Phase 4
20	The Protection of Telipression on Developing of Acute Kidney Injury in Cirrhotic Patients With Upper-gastroentestinal Bleeding	Completed	NCT04358016	Phase 4	Terlipressin;Somatostatin
21	Effects of Ilaprazole 20mg on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone Endoscopic Submucosal Dissection(ESD) for Gastric Adenoma or Early Gastric Cancer.	Completed	NCT02638584	Phase 4	Ilaprazole;Rabeprazole
22	A Prospective Study Comparing Urgent Video Capsule Endoscopy With Urgent Double-balloon Enteroscopy in Patients With Massive Overt Obscure Gastrointestinal Bleeding	Completed	NCT01654770	Phase 4
23	Administration of Intravenous Proton Pump Inhibitor Prior to Endoscopy [APPE] in Patients With Upper Gastrointestinal Bleeding; a Double-Blind Placebo-Controlled Randomised Study.	Completed	NCT00164866	Phase 4	Omeprazole
24	Randomized Controlled Trial of Wireless Capsule Endoscopy in the Evaluation of Obscure Gastrointestinal Bleeding	Completed	NCT01006824	Phase 4
25	Stress Ulcer Prophylaxis in the Intensive Care Unit (SUP-ICU)	Completed	NCT02467621	Phase 4	Pantoprazole
26	Stress Ulcer Prophylaxis Versus Placebo - a Blinded Randomized Control Trial to Evaluate the Safety of Two Strategies in Critically Ill Infants With Congenital Heart Disease	Completed	NCT03667703	Phase 4	Famotidine;Placebo
27	Single-dose Linaclotide for Capsule Endoscopy Preparation	Completed	NCT02465385	Phase 4	Linaclotide
28	Effects of Different Omeprazole Dosing on Gastric pH in Non- Variceal Upper Gastrointestinal Bleeding: A Randomized Prospective Study	Completed	NCT03980496	Phase 4	Omeprazole
29	Uninterrupted Clopidogrel Therapy Before Elective Colonoscopy Will Increase the Risk of Post-polypectomy Bleeding	Completed	NCT01806090	Phase 4	clopidogrel
30	Randomized Controlled Trial to Compare Treatment With Oral Anticoagulation With Antagonists of vitaminK vs Low Molecular Weight Heparin(Bemiparin) in Patients With Anticoagulation Criteria and an Episode of Gastrointestinal Bleeding.	Completed	NCT01727453	Phase 4	warfarin;Bemiparina
31	Prevention of Recurrent Ulcer Bleeding in Patients With Idiopathic Gastroduodenal Ulcer: a Double-blind Randomised Trial on Misoprostol Combined With Lansoprazole Versus Lansoprazole Alone (NRT_MISO Study)	Recruiting	NCT03675672	Phase 4	Misoprostol Oral Tablet;Placebo Oral Tablet
32	The Efficacy of Metoclopramide for Gastric Visualization by Endoscopy in Patients With Acute Upper Gastrointestinal Bleeding: Double-blind Randomized Controlled Trial	Recruiting	NCT04771481	Phase 4	Metoclopramide;Normal Saline 10 mL Injection
33	Comparison of 24-hours Versus 72-hours of Octreotide Infusion Along With Endoscopic Therapy in Preventing Early Rebleed From Esophageal Varices: a Multi-center, Randomized Clinical Study	Recruiting	NCT03624517	Phase 4	Octreotide
34	Examining the Effect of Ondansetron on Bowel Prep Success	Recruiting	NCT05439772	Phase 4	Ondansetron
35	A Comparison Between a High Dose PPI Intravenous Infusion and Oral Acid Pump Inhibitors After Endoscopic Haemostasis to Bleeding Peptic Ulcers	Not yet recruiting	NCT05582174	Phase 4	Vonoprazan;esomeprazole
36	Intravenous Ferric Carboxymaltose Versus Oral Ferrous Sulfate Replacement in Anaemia Due to Acute Nonvariceal Gastrointestinal Bleeding (FIERCE): Protocol of a Multicentre Randomised Controlled Trial	Not yet recruiting	NCT05060731	Phase 4	Oral iron supplementation;Intravenous iron supplementation
37	The Effect of Vonoprazan-based Dual Eradication Therapy vs PPI Treatment on Gastrointestinal Bleeding in ACS Patients With Hp Infection and Coronary Stents: an Open-label, Randomized, Controlled Trial	Not yet recruiting	NCT04728516	Phase 4	Vonoprazan-based dual eradication therapy for two weeks;amoxicillin;Pantoprazole
38	Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy	Withdrawn	NCT02570529	Phase 4	Albis®;Placebo
39	Oral vs Intravenous Proton Pump Inhibitor（PPI） in Patients With Peptic Ulcer Bleeding After Successful Endoscopic Therapy- a Prospective Randomized Comparative Trial	Withdrawn	NCT01123031	Phase 4	lansoprazole;esomeprazole
40	Randomized Double Blind Placebo Controlled Trial of Lactulose for the Prevention of Hepatic Encephalopathy in Cirrhotic Patients With Upper Gastrointestinal Hemorrhage	Unknown status	NCT00553423	Phase 3	Lactulose;Placebo
41	A Multicenter, Randomized, Open-label Clinical Trial Assessing the Efficacy of Octreotide in Decreasing Blood and Iron Requirements in Patients With Refractory Anaemia Due to Angiodysplasias	Unknown status	NCT02384122	Phase 2, Phase 3	Octreotide
42	A Randomised Study of the Optimal Bowel Preparation for Routine Capsule Endoscopy Using Citramag and Senna or Metoclopramide	Unknown status	NCT00275184	Phase 3	Senna;Citramag powder;Metoclopramide
43	Erythromycin Versus Gastric Lavage to Improve Quality of Endoscopic Examination in Patients With Upper Gastrointestinal Bleeding. A Prospective Randomized Trial.	Unknown status	NCT01716572	Phase 3	Erythromycin
44	Peri-operative Usage of Enteric Immune-nutrition Formula (ANOM®) Versus Standard Formula for Patients Received Major Upper Gastrointestinal Surgery	Unknown status	NCT01351883	Phase 3
45	Early Administration of Intravenous Tranexamic Acid for Upper Gastrointestinal Bleeding Prior to Endoscopy	Unknown status	NCT01713101	Phase 3	Early intravenous tranexamic acid administration;placebo
46	Efficacy of Left Atrial Appendage Closure After Gastrointestinal Bleeding	Unknown status	NCT01628068	Phase 3
47	Endoscopic Injection Sclerotherapy Versus N-butyl-2-cyanoacrylate Injection in the Management of Actively Bleeding Esophageal Varices	Unknown status	NCT03388125	Phase 3	Injection Sclerotherapy;N-butyl-2-cyanoacrylate
48	Emergency Capsule Endoscopy in Severe GI-bleeding	Completed	NCT01584869	Phase 2, Phase 3
49	Safety & Efficacy of Omeprazole Sodium Bicarbonate for the Prevention of Upper GI Bleeding in the Critically Ill	Completed	NCT00045799	Phase 3	Omeprazole sodium bicarbonate immediate release PWD/FS;Cimetidine IV
50	Efficacy of Parenteral Iron Supplementation After Gastrointestinal Bleeding in Subjects Over 65	Completed	NCT01690585	Phase 3	Ferinject 1000 mg;Sodium chlorure 0,9 %

Search NIH Clinical Center for Active Peptic Ulcer Disease

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Aluminum carbonate

Aluminum Hydroxide

Aluminum Hydroxide / Magnesium Hydroxide

Aluminum Hydroxide Gel

aluminum hydroxide, dried (USP)

basic aluminum carbonate gel

Calcium Carbonate

CALCIUM CARBONATE 1 g in 1 g ORAL POWDER

Calcium gluceptate

dihydroxyaluminum sodium carbonate

magaldrate

Magnesium Hydroxide

MILK OF MAGNESIA

Vasopressin (USP)

VASOPRESSIN TANNATE (IN OIL)

Sources

Genetic Tests for Active Peptic Ulcer Disease

Sources

Anatomical Context for Active Peptic Ulcer Disease

Organs/tissues related to Active Peptic Ulcer Disease:

MalaCards : Liver, Colon, Kidney, Lung, Heart, Small Intestine, Pancreas

Sources

Publications for Active Peptic Ulcer Disease

Articles related to Active Peptic Ulcer Disease:

(show top 50) (show all 3421)

#	Title	Authors	PMID	Year
1	Treatment and Bleeding Complications of Cancer-Associated Venous Thromboembolism: A Korean Population-Based Study. ⁶²	Kim SA...Bang SM	35764307	2022
2	Socioeconomic factors and bleeding events in patients with incident atrial fibrillation: A Finnish nationwide cohort study. ⁶²	Teppo K...Lehto M	36246774	2022
3	Clinical analysis of 99 children with Henoch-Schönlein purpura complicated with overt gastrointestinal bleeding. ⁶²	Yang Y...Zhen X	35941339	2022
4	Long-term rebleeding rate and predictive factors of rebleeding after capsule endoscopy in patients with obscure GI bleeding. ⁶²	Otani K...Fujiwara Y	35850171	2022
5	A novel bedside swallowed optical sensor for detection of upper GI bleeding. ⁶²	Mahmoud T...Storm AC	36471712	2022
6	Evaluation and Treatment of GI Bleeding in a 51-Year-Old Man. ⁶²	Robbins J...Siebenburgen C	35718224	2022
7	Risk of Bleeding Among Individuals on Direct-Acting Oral Anticoagulants: An Academic Medical Center Cohort Study. ⁶²	Gomez Lumbreras A...Malone DC	36084025	2022
8	Obscure Upper GI Bleeding After Liver Transplantation. ⁶²	Madigan S...Chung A	35863527	2022
9	Safety and efficacy of over-the-scope clips versus standard therapy for high-risk nonvariceal upper GI bleeding: systematic review and meta-analysis. ⁶²	Bapaye J...Okolo PI	35803307	2022
10	In adults using oral anticoagulants, PPI use may be associated with lower risk for upper GI bleeding. ⁶²	Stein DJ...Feuerstein JD	36315943	2022
11	INTERBLEED: Design of an International Study of Risk Factors for Gastrointestinal Bleeding and Cardiovascular Events After Gastrointestinal Bleeding. ⁶²	Bosch J...Eikelboom JW	36444363	2022
12	A Glasgow-Blatchford Bleeding Score of >2 Is a Poor Predictor of Endoscopic Intervention in Nonvariceal Upper GI Bleeding. ⁶²	Myneedu K...Ladd AM	36318950	2022
13	Patient and endoscopic characteristics and clinical outcomes in subjects with non-variceal GI bleeding referred for transarterial embolization: a single-center experience. ⁶²	Ephraim Joseph K...Abrams GA	36031627	2022
14	Recurrent Gastrointestinal Bleed Due to Small Bowel Vascular Malformation in a Patient with Turner Syndrome Diagnosed with Surgically Assisted Push Enteroscopy. ⁶²	Flores Lopez AG...Huang-Pacheco AS	36324242	2022
15	Evaluation of 30-day mortality in patients undergoing gastrointestinal endoscopy in a tertiary hospital: a 3-year retrospective survey. ⁶²	Chatelanat O...Frossard JL	36351757	2022
16	Safety and efficacy of direct oral anticoagulants in patients with anaemia and atrial fibrillation: an observational nationwide Danish cohort study. ⁶²	Al-Hussainy N...Riahi S	34931662	2022
17	Chronic Anti-Coagulation Therapy Reduced Mortality In Patients With High Cardiovascular Risk Early In COVID-19 Pandemic. ⁶²	Zaghloul MS...Zayed MA	36415466	2022
18	Gastrointestinal bleeding in patients with continuous-flow left ventricular assist devices: A comprehensive review. ⁶²	Del Rio-Pertuz G...Nair N	36334280	2022
19	Benefits and Risks Associated with Low-Dose Aspirin Use for the Primary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Control Trials and Trial Sequential Analysis. ⁶²	Wang M...Liu X	35570250	2022
20	Clinical characteristics and outcomes in patients with metastatic breast cancer and pseudocirrhosis: a single center retrospective cohort study. ⁶²	Huppert LA...Chien AJ	36319907	2022
21	A 10 cm pedunculated duodenal Brunner gland hamartoma, case report and literature review. ⁶²	Alsugair Z...Chassagne L	36270207	2022
22	Meckel diverticulum in the pediatric population: Patient presentation and performance of imaging in prospective diagnosis. ⁶²	McDonald JS...Kolbe AB	35986976	2022
23	Characteristics Associated With Failure to Rescue After Open Abdominal Aortic Aneurysm Repair. ⁶²	Camazine M...Vogel TR	36459861	2022
24	Key Considerations From a Health Authority Perspective When Proton Pump Inhibitors Are Used to Treat Gastroesophageal Reflux Disease (GERD) and Their Implications. ⁶²	Meyer JC...Godman B	36447806	2022
25	Sirolimus for management of GI bleeding in blue rubber bleb nevus syndrome: A case series. ⁶²	Duong JT...Zheng HB	36094280	2022
26	Nonsurgical periodontal treatment improved the type 2 diabetes mellitus status in smokers: A randomized controlled trial. ⁶²	Pham TAV...Nguyen VTT	36375565	2022
27	Does coprescribing nonsteroidal anti-inflammatory drugs and oral anticoagulants increase the risk of major bleeding, stroke and systemic embolism? ⁶²	Penner LS...Elliott RA	35484847	2022
28	Risk factors of active upper gastrointestinal bleeding in patients with COVID-19 infection and the effectiveness of PPI prophylaxis. ⁶²	Prasoppokakorn T...Pittayanon R	36397007	2022
29	Periprocedural Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant Undergoing a Digestive Endoscopy. ⁶²	Christopher HB...Barkun AN	36434811	2022
30	Scaling-up a pharmacist-led information technology intervention (PINCER) to reduce hazardous prescribing in general practices: Multiple interrupted time series study. ⁶²	Rodgers S...Avery AJ	36383560	2022
31	Endoscopy for the diagnosis and treatment of gastrointestinal bleeding caused by malignancy. ⁶²	Abu-Sbeih H...Wang Y	35730192	2022
32	Prevalence of H. pylori among patients undergoing coronary angiography (The HP-DAPT prevalence study). ⁶²	Huard K...Potter BJ	36198683	2022
33	Dyspepsia with alarm symptoms in patients aged less than 60 years: Is upper gastrointestinal endoscopy justified in Indian scenario? ⁶²	Kumari P...Kumar R	36308702	2022
34	Motorized Spiral Enteroscopy versus Double Balloon Enteroscopy: A Case-Matched Study. ⁶²	Chan W...Asokkumar R	36228697	2022
35	Duodenal tropism of SARS-CoV-2 and clinical findings in critically ill COVID-19 patients. ⁶²	Neuberger M...Knosel T	35182354	2022
36	Outcomes of COVID-19 in Adult Males With Hemophilia A: A Propensity Score-Matched Analysis. ⁶²	Mericliler M...Narayan G	36439567	2022
37	Duodenal gastrointestinal stromal tumor: A case report. ⁶²	Yadav SK...Kadel G	36268398	2022
38	An unusual and life-threatening presentation of a large GIST. ⁶²	Saeidi N...Al Safi S	36162355	2022
39	Impact of baseline renal function on the efficacy and safety of different Anticoagulants in Atrial Fibrillation Patients - A cohort study. ⁶²	Lee WC...Chen MC	36229879	2022
40	Hepatic arterial haemorrhage caused by duodenal ulcer. ⁶²	Caragher S...Fagenholz P	36316056	2022
41	Recurrent bleeding duodenal and colonic ulcers due to post-transplant lymphoproliferative disorder. ⁶²	Mitsuhashi S...Coben R	36251246	2022
42	Gastric antral vascular ectasia (Watermelon stomach); an unusual cause of upper gastrointestinal bleeding in elderly: A case report. ⁶²	Lageju N...Gnawali A	36268406	2022
43	Early lactate clearance for predicting outcomes in patients with gastrointestinal bleeding. ⁶²	Kim K...Bae SJ	36229587	2022
44	Out of sight for the endoscopist? Gastrointestinal bleeding after aortic repair. ⁶²	Busch M...Mederacke I	35527697	2022
45	A Retrospective Analysis of Risk Factors for Mortality during Hemodialysis at a General Hospital that Treats Comprehensive Diseases. ⁶²	Kitajima A...Tomiyoshi Y	36104191	2022
46	Pedunculated gastritis cystica profunda polyp presenting with upper GI bleeding and volcano-like surface alteration. ⁶²	Zimmer V...Heinrich C	34162509	2022
47	Range and consistency of gastrointestinal outcomes reported in peritoneal dialysis trials: A systematic review. ⁶²	Hayat A...Johnson DW	36127835	2022
48	Are Proton Pump Inhibitors More Effective Than Histamine-2-Receptor Antagonists for Stress Ulcer Prophylaxis in Critically Ill Patients? A Systematic Review and Meta-Analysis of Cohort Studies. ⁶²	He N...Zhai S	34971320	2022
49	Delayed hemorrhagic gastritis caused by immunotherapy in a patient With metastatic melanoma. ⁶²	Elmasry M...Miller D	35276075	2022
50	A jejunal gastrointestinal stromal tumor with massive gastrointestinal hemorrhage treated by emergency surgery: A case report. ⁶²	Jablonska B...Mrowiec S	36107510	2022

Sources

Genes for Active Peptic Ulcer Disease

Genes related to Active Peptic Ulcer Disease (0 elite genes):

(show all 19)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	ATP12A	ATPase H+/K+ Transporting Non-Gastric Alpha2 Subunit	Protein Coding	8.83	DISEASES inferred ¹⁴
2	ATP4A	ATPase H+/K+ Transporting Subunit Alpha	Protein Coding	8.83	DISEASES inferred ¹⁴
3	F2	Coagulation Factor II, Thrombin	Protein Coding	7	DISEASES inferred ¹⁴
4	VWF	Von Willebrand Factor	Protein Coding	6.68	DISEASES inferred ¹⁴
5	ACVRL1	Activin A Receptor Like Type 1	Protein Coding	6.67	DISEASES inferred ¹⁴
6	ALB	Albumin	Protein Coding	6.62	DISEASES inferred ¹⁴
7	F3	Coagulation Factor III, Tissue Factor	Protein Coding	6.48	DISEASES inferred ¹⁴
8	KIT	KIT Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	6.45	DISEASES inferred ¹⁴
9	CYP2C19	Cytochrome P450 Family 2 Subfamily C Member 19	Protein Coding	6.37	DISEASES inferred ¹⁴
10	P2RY12	Purinergic Receptor P2Y12	Protein Coding	6.31	DISEASES inferred ¹⁴
11	ANO1	Anoctamin 1	Protein Coding	6.24	DISEASES inferred ¹⁴
12	CRP	C-Reactive Protein	Protein Coding	6.18	DISEASES inferred ¹⁴
13	PTGS2	Prostaglandin-Endoperoxide Synthase 2	Protein Coding	6.14	DISEASES inferred ¹⁴
14	HRH2	Histamine Receptor H2	Protein Coding	6.12	DISEASES inferred ¹⁴
15	SST	Somatostatin	Protein Coding	6.04	DISEASES inferred ¹⁴
16	GPT	Glutamic--Pyruvic Transaminase	Protein Coding	5.96	DISEASES inferred ¹⁴
17	CYGB	Cytoglobin	Protein Coding	5.95	DISEASES inferred ¹⁴
18	PTGS1	Prostaglandin-Endoperoxide Synthase 1	Protein Coding	5.88	DISEASES inferred ¹⁴
19	F7	Coagulation Factor VII	Protein Coding	5.83	DISEASES inferred ¹⁴

Sources

Variations for Active Peptic Ulcer Disease

Sources

Expression for Active Peptic Ulcer Disease

Search GEO for disease gene expression data for Active Peptic Ulcer Disease.

Sources

Pathways for Active Peptic Ulcer Disease

Pathways related to Active Peptic Ulcer Disease according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) ⁶⁶ Show member pathways Blood clotting cascade ⁷⁴ Blood Coagulation Signaling Pathways ⁶⁵ Common Pathway of Fibrin Clot Formation ⁶⁶ Complement and coagulation cascades ⁷⁴ Defective F8 binding to von Willebrand factor ⁶⁶ Defective F8 cleavage by thrombin ⁶⁶ Defective F8 sulfation at Y1699 ⁶⁶ Defective F9 activation ⁶⁶ Defective F9 secretion ⁶⁶ Defective factor IX causes hemophilia B ⁶⁶ Defective factor VIII causes hemophilia A ⁶⁶ Defective factor XII causes hereditary angioedema ⁶⁶ Defective gamma-carboxylation of F9 ⁶⁶ Diseases of hemostasis ⁶⁶ Extrinsic Pathway of Fibrin Clot Formation ⁶⁶ Extrinsic Prothrombin Activation Pathway ⁶⁴ Formation of Fibrin Clot (Clotting Cascade) ⁶⁶ Intrinsic Pathway of Fibrin Clot Formation ⁶⁶ Thrombin/protease-activated receptor (PAR) pathway ⁶¹	12.19	VWF F7 F3 F2
2	Angiogenesis (CST) ³	11.49	VWF PTGS2 F3
3	Platelet Aggregation Inhibitor Pathway, Pharmacodynamics ⁶⁰	10.73	VWF PTGS1 P2RY12 F2 CYP2C19
4	Overview of nanoparticle effects ⁷⁴	10.61	PTGS2 PTGS1 CRP
5	Biomarkers for urea cycle disorders ⁷⁴	10.48	GPT F7
6	Aspirin and miRNAs ⁷⁴	10.32	PTGS2 PTGS1
7	Secretion of hydrochloric acid in parietal cells ⁷⁴	9.86	HRH2 ATP4A
8	Dipyrone Pathway, Pharmacokinetics/Pharmacodynamics ⁶⁰ Show member pathways COX reactions ⁶⁶	9.83	PTGS2 PTGS1 CYP2C19

Sources

GO Terms for Active Peptic Ulcer Disease

Cellular components related to Active Peptic Ulcer Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular space	GO:0005615	9.93	VWF SST KIT GPT F7 F3
2	serine-type peptidase complex	GO:1905286	8.92	F7 F3

Biological processes related to Active Peptic Ulcer Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cellular oxidant detoxification	GO:0098869	9.76	PTGS2 PTGS1 CYGB ALB
2	blood coagulation	GO:0007596	9.61	VWF P2RY12 F7 F3 F2
3	positive regulation of platelet-derived growth factor receptor signaling pathway	GO:0010641	9.56	F7 F3
4	hemostasis	GO:0007599	9.17	VWF P2RY12 F7 F3 F2

Molecular functions related to Active Peptic Ulcer Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	heme binding	GO:0020037	9.97	PTGS2 PTGS1 CYP2C19 CYGB
2	peroxidase activity	GO:0004601	9.8	PTGS2 PTGS1 CYGB
3	oxygen binding	GO:0019825	9.73	CYP2C19 CYGB ALB
4	P-type sodium:potassium-exchanging transporter activity	GO:0005391	9.71	ATP4A ATP12A
5	P-type potassium:proton transporter activity	GO:0008900	9.26	ATP4A ATP12A
6	P-type potassium transmembrane transporter activity	GO:0008556	9.16	ATP4A ATP12A
7	prostaglandin-endoperoxide synthase activity	GO:0004666	8.92	PTGS2 PTGS1